pigott
transmiss
fine
particl
aerosol
potenti
droplet
aerosol
spread
virus
larg
respons
intens
academ
militari
interest
agent
work
group
civilian
biodefens
recent
publish
analysi
potenti
vhf
agent
use
bioterrorist
weapon
emphas
great
infect
eas
transmiss
risk
public
health
high
mortal
associ
infecti
agent
reason
biolog
weapon
potenti
hemorrhag
fever
virus
weapon
former
soviet
union
unit
state
part
previou
biolog
weapon
program
confirm
use
agent
report
dr
ken
alibek
former
deputi
director
oncemass
soviet
bioweapon
program
biopreparat
claim
soviet
scientist
success
produc
stabl
marburg
viru
biolog
weapon
could
deliv
aerosol
hemorrhag
fever
virus
also
interest
terrorist
group
aum
shinrikyo
japanes
religi
cult
behind
tokyo
subway
sarin
ga
attack
sent
member
africa
obtain
sampl
ebola
viru
use
bioweapon
unsuccess
secur
viru
use
vhf
agent
biolog
weapon
subject
avid
specul
popular
media
dramat
book
film
show
panick
populac
throe
rapidli
spread
epidem
realiti
like
far
less
cinemat
although
public
percept
risk
may
lead
signific
social
econom
disrupt
like
method
spread
vhf
finedroplet
aerosol
although
contamin
surfac
food
water
potenti
sourc
infect
terrorist
group
equip
suffici
suppli
highli
contagi
vhf
agent
ebola
marburg
environment
stabl
form
could
caus
mass
casualti
event
high
morbid
mortal
multipl
studi
nonhuman
primat
document
aerosol
spread
ebola
viru
droplet
spread
suspect
mode
diseas
transmiss
among
infect
human
although
humantohuman
aerosol
transmiss
appear
rare
although
speci
famili
filovirus
ebola
marburg
like
repres
greatest
bioterror
threat
vhf
agent
also
transmiss
droplet
spread
aerosol
transmiss
lassa
viru
speci
genu
arenaviru
endem
western
africa
document
nonhuman
primat
laboratori
condit
outbreak
nigeria
index
patient
transmit
lassa
patient
hospit
ward
transmiss
thought
way
droplet
aerosol
spread
lassa
viru
infect
virus
famili
arenavirus
junin
typic
acquir
way
aerosol
infect
rodent
excreta
particularli
urin
laboratori
worker
work
agent
becom
infect
inhal
aerosol
similar
laboratoryrel
aerosol
transmiss
also
describ
yellow
fever
commonli
document
method
filoviru
transmiss
direct
contact
blood
bodi
fluid
tissu
infect
person
nonhuman
primat
recent
review
wild
anim
mortal
human
ebola
outbreak
gabon
republ
congo
conclud
human
ebola
outbreak
region
result
handl
infect
wild
anim
carcass
analysi
carcass
reveal
gorilla
chimpanze
duiker
small
african
deer
infect
ebola
discoveri
wild
anim
infect
ebola
establish
anim
natur
filoviru
reservoir
ebola
rapidli
fatal
anim
suggest
natur
host
research
natur
host
ebola
ongo
recent
work
suggest
small
mammal
littl
contact
human
bat
may
natur
reservoir
filovirus
ebola
marburg
ebola
outbreak
uganda
death
presumpt
case
patient
three
import
mean
diseas
transmiss
identifi
outbreak
ritual
contact
bodi
deceas
patient
intrafamili
transmiss
nosocomi
spread
addit
health
care
worker
involv
care
patient
infect
ebola
also
infect
despit
establish
isol
ward
stricter
infect
control
measur
institut
diseas
contain
achiev
eas
persontoperson
transmiss
ebola
viru
support
presenc
ebola
viru
skin
sweat
gland
infect
person
document
immunohistochem
assay
convers
outbreak
marburg
viru
infect
durba
republ
congo
case
clear
persontoperson
transmiss
could
verifi
caus
agent
behind
ongo
outbreak
hemorrhag
fever
angola
began
octob
recent
identifi
marburg
viru
epidemiolog
studi
outbreak
still
underway
appear
identifi
case
die
death
children
rout
transmiss
infect
yet
known
although
small
number
health
care
worker
alreadi
infect
primari
mode
initi
arenaviru
infect
aerosol
rodent
excreta
typic
urin
rodent
natur
reservoir
arenavirus
persontoperson
transmiss
arenavirus
lassa
isa
filovirusesprimarili
via
contact
infect
blood
bodi
fluid
primari
patholog
defect
patient
vhf
increas
vascular
permeabl
hemorrhag
fever
virus
affin
vascular
system
lead
initi
sign
flush
conjunctiv
inject
petechi
hemorrhag
usual
associ
fever
myalgia
later
frank
mucou
membran
hemorrhag
may
occur
accompani
hypotens
shock
circulatori
collaps
rel
sever
clinic
present
may
vari
depend
viru
question
amount
rout
exposur
acut
diseas
patient
extrem
virem
messeng
rna
mrna
evid
multipl
cytokin
activ
exist
vitro
studi
reveal
cytokin
lead
shock
increas
vascular
permeabl
basic
pathophysiolog
process
often
seen
vhf
infect
anoth
promin
patholog
featur
pronounc
macrophag
involv
inadequ
delay
immun
respons
novel
viral
antigen
may
lead
rapid
develop
overwhelm
viremia
extens
infect
necrosi
affect
organ
also
describ
hemorrhag
complic
multifactori
relat
hepat
damag
consumpt
coagulopathi
primari
marrow
injuri
megakaryocyt
increas
vascular
permeabl
vhf
infect
thought
secondari
endotheli
injuri
immunolog
factor
rather
direct
viral
mediat
endotheli
injuri
direct
damag
endotheli
cell
caus
viralinduc
cytolysi
describ
caus
bleed
diathesi
ebola
viru
infect
multisystem
organ
failur
affect
hematopoiet
neurolog
pulmonari
system
often
accompani
vascular
involv
hepat
involv
vari
infect
organ
time
seen
ebola
marburg
well
vhf
agent
yellow
fever
renal
failur
oliguria
although
promin
featur
hemorrhag
fever
renal
syndrom
hfr
seen
hantaviru
infect
may
seen
vhf
infect
intravascular
volum
deplet
becom
pronounc
bleed
complic
particularli
promin
ebola
marburg
south
american
arenavirus
although
data
exist
laboratorybas
vhf
infect
anim
model
clinic
inform
regard
vhf
infect
come
natur
occur
outbreak
suspicion
vhf
infect
area
virus
endem
high
patient
present
even
nonspecif
symptom
viral
infect
high
fever
headach
fatigu
myalgia
abdomin
pain
nonbloodi
diarrhea
constel
symptom
well
describ
initi
prodrom
period
vhf
infect
follow
terrorist
incid
septemb
cdc
releas
instruct
recogn
ill
associ
releas
biolog
agent
list
clinic
find
associ
marburg
ebola
viru
infect
abrupt
onset
fever
headach
myalgia
follow
nausea
vomit
abdomin
pain
chest
pain
macularpapular
rash
particularli
involv
trunk
although
clinic
present
may
rais
specter
vhf
infect
routin
emerg
depart
set
unit
state
europ
sever
recent
case
import
vhf
infect
endem
area
industri
countri
report
eas
rapid
global
travel
like
increas
spread
unusu
pathogen
includ
vhf
agent
august
businessman
made
sever
recent
trip
liberia
sierra
leon
west
africa
present
new
jersey
emerg
depart
fever
chill
sore
throat
diarrhea
back
pain
condit
deterior
rapidli
hospit
requir
intub
mechan
ventil
diagnos
consid
includ
yellow
fever
lassa
fever
well
typhoid
fever
malaria
despit
aggress
support
therapi
patient
die
postmortem
examin
confirm
diagnosi
lassa
fever
serum
antigen
detect
viral
cultur
revers
transcriptas
polymeras
chain
reaction
rtpcr
assay
none
patient
identifi
contact
either
within
hospit
hospit
report
symptom
consist
lassa
viru
infect
incub
period
vhf
agent
rang
day
nonspecif
prodrom
symptom
vhf
infect
note
often
variabl
differ
vhf
agent
well
filovirus
ebola
marburg
tend
rapid
onset
symptom
arenaviru
infect
may
slower
progress
target
vhf
infect
vascular
system
symptom
endotheli
damag
increas
vascular
permeabl
tend
predomin
earli
infect
patient
present
conjunctiv
inject
mild
hypotens
flush
petechi
rash
later
stage
diseas
frank
mucou
membran
hemorrhag
shock
gener
bleed
may
occur
involv
neurolog
pulmonari
hematopoiet
system
may
also
occur
lassa
fever
hemorrhag
complic
tend
less
common
filoviru
infect
deaf
common
longterm
complic
signific
lassa
fever
infect
evid
hepat
injuri
jaundic
seen
ebola
marburg
yellow
fever
morbid
mortal
associ
vhf
infect
highli
variabl
ebola
strain
ebolazair
outbreak
kikwit
democrat
republ
congo
case
fatal
rate
uganda
outbreak
case
fatal
rate
strain
ebola
isol
uganda
outbreak
ebolasudan
one
four
ebola
subtyp
previous
describ
other
includ
virul
ebolazair
case
fatal
rate
ebolacot
divoir
ebolareston
variant
first
describ
reston
virginia
appear
affect
nonhuman
primat
arenaviru
infect
typic
result
mortal
rate
lassa
fever
new
world
arenavirus
patient
lassa
fever
either
mild
observ
symptom
sever
diseas
occur
infect
mode
vhf
exposur
correl
degre
ill
particularli
filoviru
infect
percutan
acquisit
diseas
strongli
correl
increas
mortal
ebolazair
outbreak
everi
case
infect
caus
contamin
syring
result
death
african
south
american
health
care
set
diagnosi
vhf
infect
far
like
industri
nation
infrequ
vhf
ill
industri
countri
initi
evalu
pigott
patient
suspect
import
vhf
infect
attempt
provid
support
therapi
specif
antivir
agent
appropri
also
rule
common
pathogen
may
specif
therapi
differenti
diagnosi
vhf
encompass
wide
array
infecti
noninfecti
etiolog
viral
bacteri
ill
may
mimic
vhf
includ
influenza
viral
hepat
staphylococc
gramneg
sepsi
meningococcemia
salmonellosi
shigellosi
well
less
common
infect
leptospirosi
malaria
rickettsi
diseas
rocki
mountain
spot
fever
dengu
hantaviru
noninfecti
caus
caus
bleed
diathesi
includ
dissemin
intravascular
coagul
dic
idiopath
thrombot
thrombocytopen
purpura
hemolyticurem
syndrom
acut
leukemia
collagenvascular
diseas
potenti
signific
delay
diagnosi
vhf
infect
like
relat
rariti
infect
set
routin
emerg
depart
icu
care
natur
occur
case
vhf
infect
patient
gener
histori
travel
local
vhf
infect
endem
west
central
africa
south
america
contact
infect
peopl
anim
arthropod
vector
yellow
fever
case
bioterrorist
attack
warn
would
like
forthcom
present
number
febril
patient
variou
nonspecif
constitut
symptom
would
difficult
link
common
infecti
sourc
anthrax
bioterror
attack
share
rout
exposur
serv
identifi
infect
individu
well
potenti
risk
infect
virul
infecti
agent
special
contain
procedur
requir
handl
safe
introduc
signific
delay
definit
diagnosi
hospit
microbiolog
laboratori
local
public
health
facil
equip
diagnos
vhf
infect
sampl
must
sent
either
center
diseas
control
prevent
atlanta
georgia
us
armi
medic
research
institut
infecti
diseas
usamriid
frederick
maryland
event
bioterrorist
attack
involv
larg
number
infect
patient
triag
system
would
enact
alloc
avail
health
care
resourc
meet
patient
demand
rapid
progress
diseas
particularli
patient
filoviru
infect
difficult
establish
patient
greatest
chanc
surviv
follow
averag
incub
time
day
ebola
marburg
infect
onset
diseas
rapid
death
usual
occur
within
day
onset
ill
ebola
outbreak
uganda
temporari
diagnost
laboratori
establish
onsit
abl
perform
rapid
nextday
test
ebola
viru
viral
antigen
captur
elisa
rtpcr
retrospect
analysi
data
obtain
field
laboratori
also
demonstr
viral
load
correl
diseas
outcom
viral
rna
copi
level
patient
die
time
higher
among
surviv
infect
rna
copi
level
ml
higher
associ
fatal
outcom
posit
predict
valu
n
although
somewhat
intuit
ie
patient
demonstr
evid
overwhelm
viremia
wors
data
suggest
potenti
guidelin
manag
mass
casualti
incid
involv
vhf
infect
vhf
patient
least
confirm
filoviru
infect
document
evid
sever
viremia
unlik
benefit
aggress
resuscit
measur
potenti
save
resourc
patient
better
chanc
surviv
may
result
improv
overal
surviv
among
infect
patient
design
use
rural
health
care
set
limit
resourc
set
guidelin
care
vhf
patient
creat
jointli
cdc
world
health
organ
serv
model
appropri
patient
care
minim
risk
health
care
provid
noninfect
person
pigott
optim
use
avail
resourc
fig
african
filoviru
outbreak
infect
patient
group
isol
ward
separ
area
health
care
personnel
chang
protect
cloth
industri
countri
resourc
typic
avail
isol
precaut
gener
requir
one
two
patient
set
bioterror
attack
involv
vhf
agent
howev
signific
number
symptomat
patient
may
expect
potenti
sever
ill
estim
number
patient
requir
critic
care
difficult
case
fatal
rate
vhf
agent
vari
high
suggest
number
infect
patient
might
requir
critic
care
servic
like
repres
least
symptomat
patient
perhap
nearli
patient
virul
form
filoviru
infect
need
intens
care
patient
clearli
demonstr
recent
describ
case
import
vhf
nurs
hospit
vhf
symptom
later
diagnos
ebolazair
south
africa
develop
sever
hemorrhag
complic
ultim
die
intracerebr
hemorrhag
death
requir
prolong
intens
care
includ
day
mechan
ventil
well
signific
fluid
resuscit
blood
product
infus
underw
multipl
invas
procedur
includ
two
laparotomi
hemodialysi
pulmonari
arteri
catheter
vasopressor
infus
persist
hypotens
patient
care
johannesburg
hospit
intens
care
unit
specif
design
patient
hemorrhag
fever
care
attent
strict
barrier
precaut
like
respons
absenc
transmiss
ill
patient
hospit
essenti
prioriti
health
care
facil
personnel
care
patient
confirm
suspect
vhf
infect
contain
diseas
filovirus
arenavirus
highli
infecti
direct
contact
blood
bodili
secret
given
risk
health
care
provid
demonstr
previou
natur
occur
vhf
outbreak
institut
appropri
barrier
precaut
neg
pressur
isol
patient
vital
ebola
outbreak
kikwit
democrat
republ
congo
infect
patient
whose
occup
known
identifi
health
care
worker
initi
barriernurs
precaut
outbreak
highli
effect
one
health
care
worker
becam
ill
institut
prevent
measur
fig
suspect
case
vhf
fever
report
hospit
epidemiologist
infect
control
offic
well
local
state
public
health
offici
laboratori
director
personnel
also
notifi
addit
precaut
institut
amongst
laboratori
personnel
notif
cdc
essenti
case
suspect
vhf
infect
expedit
virusspecif
diagnost
test
mobil
appropri
resourc
contain
epidemiolog
identif
specif
vhf
agent
beyond
scope
hospit
laboratori
pose
substanti
risk
laboratori
personnel
highli
infecti
natur
virus
even
special
facil
equip
handl
agent
accid
occur
result
unintend
infect
death
specif
infectioncontrol
recommend
care
patient
suspect
confirm
vhf
infect
includ
strict
adher
hand
wash
doubl
glove
use
imperm
gown
mask
power
airpurifi
respir
neg
pressur
isol
air
exchang
per
hour
leg
shoe
cover
face
shield
goggl
addit
contain
measur
includ
restrict
access
nonessenti
staff
visitor
dedic
medic
equip
patient
stethoscop
blood
pressur
cuff
avail
pointofcar
analyz
environment
disinfect
hospit
disinfect
approv
environment
protect
agenc
bleach
solut
multipl
potenti
infect
patient
place
part
hospit
minim
exposur
patient
health
care
worker
event
mass
casualti
incid
even
larg
nonpatientcar
space
convert
neg
pressur
area
use
portabl
higheffici
particul
air
filter
forcedair
equip
multipl
studi
infect
control
measur
institut
vhf
outbreak
document
efficaci
strict
barriercontrol
measur
markedli
reduc
elimin
risk
diseas
transmiss
patient
surviv
vhf
infect
may
remain
contagi
extend
period
time
convalesc
semen
sampl
ebola
survivor
pigott
demonstr
evid
ebola
viru
rtpcr
day
diseas
onset
although
live
viru
could
isol
patient
die
vhf
infect
promptli
cremat
buri
unnecessari
contact
corps
includ
autopsi
embalm
avoid
contact
patient
diagnos
vhf
infect
includ
hospit
personnel
laboratori
worker
place
medic
surveil
sign
vhf
infect
day
theoret
maxim
incub
period
vhf
infect
hospit
laboratori
major
academ
medic
center
lack
capabl
safe
handl
vhf
agent
patient
sampl
must
special
hand
packag
shippment
author
laboratori
analysi
usamriid
cdc
current
biosafeti
laboratori
resourc
make
virusspecif
diagnos
vhf
infect
increas
demand
contain
facil
bioterror
research
recent
led
plan
expans
facil
includ
two
new
nation
biocontain
laboratori
boston
univers
univers
texa
medic
branch
galveston
fund
nation
institut
health
barrier
inher
virusspecif
test
case
definit
presumpt
vhf
infect
develop
set
natur
occur
vhf
outbreak
use
specif
clinic
diagnost
criteria
box
case
definit
develop
ebola
viru
infect
kikwit
outbreak
use
presenc
fever
visibl
sign
bleed
bleed
gum
nose
conjunctiv
hemorrhag
ecchymosi
hematochezia
melena
hematemesi
criteria
includ
fever
without
sign
bleed
person
contact
patient
suspect
ebola
viru
infect
clear
concis
case
definit
suspect
vhf
infect
serv
appropri
initi
screen
tool
set
suspect
vhf
outbreak
might
caus
act
bioterror
scenario
larg
volum
patient
specimen
requir
definit
viral
identif
would
like
labor
intens
time
consum
potenti
result
signific
delay
diagnosi
special
laboratori
virusspecif
diagnos
vhf
agent
made
use
sever
method
includ
viral
antigencaptur
elisa
rtpcr
viral
isol
kikwit
ebola
outbreak
cdc
research
use
viral
antigencaptur
elisa
assay
well
immunohistochem
stain
formalinfix
tissu
sampl
use
specif
polyclon
antibodi
recent
filoviru
outbreak
field
laboratori
capabl
perform
viral
antigencaptur
elisa
well
rtpcr
establish
allow
health
care
personnel
access
highli
specif
diagnost
assay
without
substanti
delay
specimen
process
use
larg
autom
portabl
thermal
cycler
prepar
biolog
sampl
dna
rna
rtpcr
identif
anyon
present
fever
sign
bleed
bleed
gum
bleed
nose
red
eye
bleed
skin
purpl
color
patch
skin
bloodi
dark
stool
vomit
blood
unexplain
sign
bleed
whether
histori
contact
suspect
case
ehf
anyon
live
deceas
contact
suspect
case
ehf
histori
fever
without
sign
bleed
reduc
potenti
hazard
exposur
laboratori
personnel
highli
infecti
biolog
agent
diagnosi
lassa
fever
elisa
assay
recent
prove
reliabl
indirect
fluoresc
antibodi
test
previou
standard
method
viral
identif
junin
viru
caus
argentin
hemorrhag
fever
identifi
use
elisa
assay
detect
junin
igg
antibodi
infect
rodent
recent
pcr
assay
becom
avail
lassa
junin
pcr
develop
predict
amplifi
member
arenavirida
famili
target
highli
conserv
rna
termin
segment
treatment
vhf
infect
primarili
support
antivir
drug
approv
us
food
drug
administr
use
set
vhf
infect
howev
small
publish
trial
shown
intraven
ribavirin
nucleosid
analog
markedli
reduc
level
guanosin
monophosph
guanosin
diphosph
guanosin
triphosph
use
treat
lassa
fever
signific
reduct
mortal
similar
result
shown
use
intraven
ribavirin
treatment
new
world
arenavirus
well
ribavirin
avail
compassion
use
investig
new
drug
protocol
antivir
agent
proven
effect
either
ebola
marburg
infect
develop
filoviru
viru
vaccin
signific
focu
ongo
research
effort
ebola
dna
plasmid
vaccin
reli
dna
primer
three
strain
ebola
viru
recent
complet
nihsponsor
phase
human
trial
activ
followup
phase
howev
data
yet
avail
anoth
team
research
current
focus
ebola
vaccin
base
nonvirul
ebola
viru
protein
stimul
antibodyand
cellmedi
host
immun
respons
group
also
describ
similar
protect
marburg
viru
infect
use
marburg
viruslik
particl
ebola
proteinbas
vaccin
current
undergo
primat
studi
efficaci
ebola
vaccin
human
understand
difficult
assess
clinic
given
unlik
scenario
healthi
human
volunt
would
consent
expos
live
wildtyp
ebola
viru
even
vaccin
research
vaccin
lassa
viru
new
world
arenavirus
ongo
cdc
although
addit
fund
recent
becom
avail
lassa
viru
research
difficulti
conduct
vaccin
trial
endem
area
lack
polit
stabil
region
remain
signific
obstacl
vaccin
develop
test
live
attenu
viru
vaccin
argentin
hemorrhag
fever
junin
avail
effect
may
protect
bolivian
hemorrhag
fever
caus
machupo
viru
well
set
bioterrorist
attack
use
vhf
bioweapon
vaccin
viabl
solut
follow
vaccin
antibodi
titer
tend
rise
slowli
typic
requir
month
confer
full
immun
treatment
person
alreadi
infect
vhf
agent
subject
intens
research
interest
particularli
given
increas
number
recent
natur
occur
filoviru
outbreak
use
convalesc
serum
ie
sera
patient
surviv
infect
suggest
possibl
therapi
late
kikwit
outbreak
eight
ebola
patient
receiv
whole
blood
transfus
ebola
survivor
seven
surviv
howev
clear
evid
link
surviv
directli
therapi
clear
demonstr
benefit
gener
data
use
immun
plasma
prove
effect
treatment
arenavirus
includ
junin
machupo
although
difficulti
plasma
collect
storag
may
limit
effect
therapi
novel
antivir
regimen
success
vitro
studi
lassa
ebola
sever
acut
respiratori
syndrom
sar
coronaviru
addit
block
viral
replic
recent
effort
attempt
target
vhf
diseas
process
inhibit
action
proinflammatori
cytokin
therebi
attenu
consumpt
coagulopathi
hallmark
diseas
current
howev
effect
therapi
vhf
infect
ribavirin
patient
lassa
fever
new
world
arenaviru
infect
treatment
filoviru
infect
remain
support
treatment
vhfinfect
patient
present
substanti
difficulti
complic
need
maintain
strict
barrier
control
prevent
transmiss
vhf
infect
treat
health
care
laboratori
personnel
need
administ
fluid
electrolyt
blood
product
like
signific
patient
patient
lassa
fever
dehydr
edema
hypotens
renal
insuffici
common
use
invas
procedur
howev
minim
reduc
risk
staff
iatrogen
transmiss
potenti
lethal
pathogen
publish
descript
import
case
vhf
infect
time
diagnosi
often
significantli
delay
return
sierra
leon
west
africa
surgeon
hospit
netherland
work
diagnosi
typhoid
fever
diagnos
lassa
fever
day
die
day
later
despit
initi
ribavirin
therapi
diagnosi
unprotect
contact
identifi
investig
contact
none
show
seroconvers
lassa
viru
antibodi
screen
although
diagnosi
case
delay
methicillinresist
staphylococcu
aureu
mrsa
contact
isol
precaut
institut
earli
patient
hospit
need
volum
resuscit
patient
vhf
infect
greatest
late
stage
infect
patient
develop
worsen
hemorrhag
shock
shown
viral
load
also
tend
higher
later
stage
infect
may
increas
infect
blood
bodi
fluid
despit
intuit
concept
sickest
patient
may
benefit
highest
level
care
clear
evid
vigor
resuscit
sever
symptomat
vhf
patient
lead
decreas
mortal
kikwit
ebola
outbreak
howev
increas
incid
cough
hemoptysi
among
survivor
thought
perhap
reflect
increas
use
parenter
fluid
resuscit
later
outbreak
data
avail
regard
care
vhf
patient
modern
emerg
depart
intens
care
unit
set
confin
isol
case
report
clear
gener
regard
improv
patient
outcom
deriv
recent
naturallyoccur
outbreak
ebola
marburg
viru
patient
care
isol
ward
group
togeth
similarli
infect
patient
lack
individu
isol
decontamin
treatment
facil
typic
clinic
cours
patient
vhf
infect
gener
vhf
patient
caus
organ
close
link
patient
clinic
cours
overal
outcom
vhf
agent
arenavirus
rel
low
incid
hemorrhag
side
effect
other
ebola
marburg
tend
follow
fulmin
cours
previous
note
patient
lassa
fever
tend
mild
clinic
cours
infect
ebolazair
may
experi
case
fatal
rate
presenc
signific
volum
deplet
coupl
hemodynam
instabl
poor
prognost
sign
patient
vhf
infect
largest
case
studi
ebolazair
infect
termin
ill
patient
typic
present
sign
sever
volum
loss
includ
obtund
anuria
shock
anoth
find
note
case
seri
premorbid
find
tachypnea
among
group
patient
tachypnea
signific
criteria
differenti
fatal
nonfat
outcom
p
tachypnea
gener
associ
bleed
mucosa
punctur
site
anuria
hiccup
tachypnea
preced
death
day
prognost
factor
associ
wors
patient
outcom
also
deriv
fieldbas
genet
studi
vhf
agent
well
presenc
absenc
certain
clinic
sign
symptom
rtpcr
assay
quantit
analysi
rna
viral
load
patient
infect
ebolasudan
uganda
outbreak
use
retrospect
identifi
patient
like
fatal
outcom
presenc
edema
typic
accompani
dehydr
hypotens
identifi
poor
prognost
sign
patient
lassa
fever
review
pediatr
lassa
fever
case
identifi
swollen
babi
syndrom
consist
widespread
edema
abdomin
distens
bleed
end
death
three
four
case
absenc
thought
good
prognost
factor
children
lassa
fever
unfortun
largest
clinic
studi
vhf
patient
deriv
imperfect
combin
highli
sensit
laboratorybas
viral
assay
unreli
incomplet
clinic
data
obtain
natur
occur
outbreak
rural
third
world
health
care
set
complex
interdepend
factor
complic
develop
rigor
evidencebas
conclus
regard
expect
clinic
cours
prognost
factor
vhf
patient
urban
industri
hospit
set
stateoftheart
emerg
depart
intens
care
resourc
readili
avail
previous
unthink
prospect
bioterror
becom
post
septemb
polit
climat
proven
threat
present
substanti
ongo
risk
industri
nation
risk
requir
healthi
respect
capabl
lethal
potenti
agent
bioterror
case
viral
hemorrhag
fever
lethal
virus
repres
continu
public
health
threat
endem
area
eas
speed
global
travel
busi
travel
tourist
unwittingli
infect
deadli
pathogen
arriv
without
warn
hospit
industri
nation
present
novel
diagnost
challengesa
well
signific
new
risksto
western
health
care
worker
hospit
employe
recogn
risk
factor
natur
acquir
vhf
infect
well
sign
symptom
vhfbase
bioterror
attack
physician
health
care
worker
use
proper
barrier
precaut
evalu
manag
patient
suspect
harbor
vhf
infect
time
minim
infecti
risk
highli
contagi
potenti
lethal
pathogen
